Suton P, et al. - Researchers analyzed 1,665 subjects to examine the effectiveness of cisplatin (CDDP) vs cetuximab (C225) given with radiotherapy for p16-positive oropharyngeal cancer (OPC). They calculated 0.45 as the pooled OR for CDDP-based chemoradiotherapy vs C225-based bioradiotherapy, and pooled OR for CDDP-based chemoradiotherapy vs C225-based bioradiotherapy value was 0.35. They found a 2.2- and 2.9-fold lower risk of death from any cause and locoregional recurrence (LRR) among subjects receiving CDDP with irradiation, respectively. They suggested CDDP-based chemoradiotherapy should continue to be the standard of treatment of p16-positive OPC.